These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10049736)

  • 1. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
    van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
    Biochem Biophys Res Commun; 1999 Feb; 255(2):491-4. PubMed ID: 10049736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
    van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
    Biochem Biophys Res Commun; 1999 Oct; 264(1):108-11. PubMed ID: 10527849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K; Dunford JE; Ebetino FH; Rogers MJ
    Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
    Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoprenoid enzyme systems of silkworm. I. Partial purification of isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthetase, and geranylgeranyl pyrophosphate synthetase.
    Koyama T; Matsubara M; Ogura K
    J Biochem; 1985 Aug; 98(2):449-56. PubMed ID: 4066649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
    van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
    Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
    Frith JC; Rogers MJ
    J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
    Sanders JM; Gómez AO; Mao J; Meints GA; Van Brussel EM; Burzynska A; Kafarski P; González-Pacanowska D; Oldfield E
    J Med Chem; 2003 Nov; 46(24):5171-83. PubMed ID: 14613320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
    Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
    J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.